Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial
- 18 June 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 380 (9838) , 238-246
- https://doi.org/10.1016/s0140-6736(12)60570-4
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Bildung und Forschung (01Gi0204, B11)
This publication has 29 references indexed in Scilit:
- Pathophysiological Mechanisms of Atrial Fibrillation: A Translational AppraisalPhysiological Reviews, 2011
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’European Heart Journal, 2009
- Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humansNature Medicine, 2009
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2006
- Targeted pharmacological reversal of electrical remodeling after cardioversion—Rationale and design of the Flecainide Short-Long (Flec-SL) trialAmerican Heart Journal, 2005
- Amiodarone versus Sotalol for Atrial FibrillationNew England Journal of Medicine, 2005
- A simple imputation algorithm reduced missing data in SF-12 health surveysJournal of Clinical Epidemiology, 2005
- Prevention of atrial fibrillation after cardioversion: results of the PAFAC trialEuropean Heart Journal, 2004